ArticleFrontiers in aging neuroscience2025
Accurate and robust prediction of Amyloid-β brain deposition from plasma biomarkers and clinical information using machine learning.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI In Vivo Detection of Amyloid-β Protein Deposition in Different Brain Regions of Patients with AD and MCI.Brain topography · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) greatly affects the daily functioning and life quality of patients and is prevalent in the elderly population. Amyloid-β (Aβ) accumulation in the brain is the main hallmark of AD pathophysiology. Positron Emission Tomography (PET) imaging is the most accurate method to identify Aβ deposits in the brain, but it is expensive and not widely available. The development of a low-cost method to detect Aβ deposition in the brain, as an alternative to PET, would therefore be of great value. This study aims to develop and validate machine learning algorithms for accurately predicting brain Aβ positivity using plasma biomarkers, genetic information, and clinical data as a cost-effective alternative to PET imaging. Methods: We analyzed 1,043 patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and validated our models on 127 patients from the Center for Neurodegeneration and Translational Neuroscience (CNTN) dataset. Brain Aβ status was determined using plasma biomarkers [Aβ42, Aβ40, Phosphorylated tau (pTau) 181, Neurofilament light chain (NfL)], Apolipoprotein E (APOE) genotype, and clinical information [Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), age, education year, and gender]. Decision tree, random forest, support vector machine, and multilayer perceptron machine learning methods were used to combine all this information. We introduced a feature selection method to balance the performance and the number of features. We conducted a feature matching technique to enable our model to be tested on the external dataset without retraining. Results: Our system achieved a value of 0.95 for the Area Under the ROC curve (AUC) using the ADNI dataset ( Conclusion: The random forest, support vector machine and multilayer perceptron methods can accurately predict brain Aβ status using plasma biomarkers, genotype, and clinical information. The method generalizes well to an independent dataset and can be reduced to using only five features without losing much accuracy, thus providing an inexpensive alternative to PET imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.